A recent survey by the Cochrane Collaboration has found that some of the most widely used vaccines for cervical cancer (CVC) are inadequate to protect against HPV, especially in those with pre-existing conditions.
According to the study, the HPV vaccine, which is made by the GSK, is the only vaccine currently available for pre-cancerous cervical cancers.
The study analyzed the safety and effectiveness of a vaccine made by GSK and three others.
It is a Cochrane review that reviews evidence on the safety, effectiveness and tolerability of vaccines for a broad range of diseases.
It also reviews evidence for their use in adults and children.
While the study found the GBS vaccine was significantly better than the other two vaccines, the vaccine was no better than a placebo in preventing the development of cancer in women with pre to post-cancer conditions.
One of the authors of the study told the CBC that, “the results of this study indicate that the efficacy of the GBC vaccine is low.”
The study authors, Dr. Michael B. Purdy and Dr. Paul M. Condon, also reported that, when comparing GBS and GBS-H vaccine, the Gbs vaccine was superior in preventing cancer in post-treatment cervical cancer patients.
A spokesperson for GSK said that the vaccine is currently being tested for efficacy in a Phase III trial in pre-menopausal women with HPV-2, and is being studied for efficacy for women who have had their first HPV-1 vaccination.
GBS is not currently approved for use in pregnant women.
“This is a really important study and a very important piece of the puzzle for cervical screening,” Dr. Elizabeth Friesen, a cancer epidemiologist at the University of California, San Francisco, told the Huffington Post.
“There are many, many different kinds of cancers and different cancers that are very, very challenging to detect.”
Dr. Purdy told the New York Times that, in addition to the benefit of the vaccine in preventing cervical cancer, the study “provides important data on the efficacy and safety of vaccines in women.”
But she told the newspaper that, because the data is only available to GSK patients, the Cochlear study cannot definitively recommend the vaccine for women with cervical cancer.
The results of the new Cochrane study “have the potential to influence the regulatory decision of the U.S. Food and Drug Administration, and in the United States the FDA is not required to make such a decision,” she said.
“The results are important because they provide information about the efficacy, safety and tolerable dose response of the HPV vaccination.”
While the vaccine does not contain the same amount of HPV as a vaccine that contains the same type of vaccine, it does contain the active component of HPV and is administered as a shot in pill form.
The vaccine can be given as a booster shot to women who are already receiving the vaccine.
The Cochrane team, which included researchers from Canada, Germany, and the U